Mannkind (MNKD) Stock
Inhalable insulin maker for diabetes patients. Here's the price, business snapshot, and what's worth knowing about Mannkind in October 2026.
MannKind Corporation (MNKD) is a small-cap biopharmaceutical company best known for Afrezza, an inhalable insulin product for people with diabetes. Investors should know MannKind’s value proposition centres on its inhalation delivery technology and commercial efforts to grow Afrezza sales, pursue new indications and explore licensing or partnership opportunities. Financial performance can be uneven: revenue depends heavily on product uptake, distribution arrangements and any new regulatory or reimbursement developments. The company has R&D and regulatory risk typical of biotech firms, plus market competition from other diabetes therapies. MannKind does not currently offer a dividend, and its shares can be volatile. This summary is for general educational purposes only and is not personalised investment advice; always consider your risk tolerance and do further research or consult a professional before investing.
Mannkind (MNKD) Stock Forecast
Analyst price target, next 12 months
$8.06
+145.7% vs today's $3.28
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Mannkind have a consensus 12-month target of $8.06, above the current price of $3.28.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MannKind's stock as it has significant potential for price growth.
Financial Health
MannKind Corporation is generating strong revenue and cash flow, supported by a high gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Afrezza revenue potential
Afrezza is the main commercial asset and could drive growth if uptake or label expansion improves, although sales trends have been uneven and outcomes are uncertain.
Inhaled delivery focus
Proprietary inhalation technology differentiates the company and may enable licensing opportunities, but technical, regulatory and commercial hurdles remain.
Partnerships & markets
Collaborations and market access are important for scaling reach; changes in reimbursement or competitive diabetes therapies can materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
